Pharmacare Information for Health Professionals | Health

Information for Health Professionals

Pharmacy Claims Submission Procedures and Audit
Manitoba Drug Benefits Formulary and Manitoba Drug Interchangeability Formulary
Submitting New or Updated Pharmacy Information
Current Topics & Client Resources
Additional Client-Related Resources
Provincial Acts and Regulations
Contact Information

Pharmacy Claims Submission Procedures and Audit

Manitoba Health's current claim submission procedures and audit processes for community pharmacies are available below. (For all documents related to Claim Submission Procedures, the word “Manitoba” refers to “Manitoba Health.")

Notices

Notice – COVID-19

Expression of Interest for COVID-19 Oral Antiviral Drug Provision (UPDATED May 3, 2022)
COVID-19 Oral Antiviral Drug Provision Expression of Interest Form
Drug Shortage Quantity Restrictions List (UPDATED November 21, 2023)
Supply Restriction Update
EDS Extension (UPDATED April 2021)
30 – Day Supply

Notice – Pharmacy Software Vendor Price file
Notice – Tiered Biologics Reimbursement Policy
- Tiered Biologics Flowsheet (UPDATED June 2022)
- Tiered Biologics Overview (UPDATED April 2023)
- Tiered Biologics by Specialty (UPDATED April 2023)
Notice – Approved Compounds for Pain Management – January 19, 2018

Pharmacy Submission Procedure Manual (DPIN Pharmacy Manual)
The DPIN Pharmacy Manual may be updated from time to time, as communicated directly to pharmacies. The current version includes all Claims Submission Procedures and associated lists/forms provided below.

Claims Submission Procedure – Advanced Glucose Monitors (EFFECTIVE March 14, 2023)
Claims Submission Procedure – Blood Glucose Test Strips (REVISED August 24, 2023)
Claims Submission Procedure – COVID-19 Oral Antiviral Drug Provision (REVISED October 7, 2022)
COVID-19 Oral Antiviral Drug Claim Form – Client Without a Manitoba Health PHIN (EFFECTIVE May 20, 2022)
Paxlovid Order Form (REVISED March 2023)
Claims Submission Procedure – Uncomplicated Cystitis Assessment (EFFECTIVE March 7, 2022)
Claims Submission Procedure – Manitoba HIV Medication Program – Anti-Retroviral Therapies (EFFECTIVE July 12, 2021)
Claims Submission Procedure – Manitoba HIV Medication Program – Post-Exposure Prophylaxis (EFFECTIVE July 26, 2021)

Manitoba HIV Medication Program Drug List (UPDATED February 24, 2022)

Claims Submission Procedure – Insulin Pump Supplies (EFFECTIVE January 24, 2023)
- FAQ – Insulin Pump Supplies (January 2023)
Claims Submission Procedure – Professional Fee Cap
Claims Submission Procedure – Oral Oncology Drugs Dispensed at CancerCare Manitoba
- List of Oral Oncology Drugs Dispensed at CancerCare Manitoba (UPDATED October 2023)
Claims Submission Procedure – Extemporaneous Products (Compounding)
- Monitored Drugs Compound List (UPDATED March 31, 2022)
- PIN Flowsheet
Claims Submission Procedure – Outsourced Extemporaneous Products
Claims Submission Procedure – Special Authority Compounding
- Form – Special Authority Compound Worksheet
Claims Submission Procedure – Manitoba Designated Drug Shortages
- Drug Shortage PIN List to November 22, 2023
- Drug Shortage PIN – Prazosin Capsule (US Label) – revised November 7, 2023
- Drug Shortage PIN – Sabril 500mg tab (US Label) – effective July 12, 2023
- Drug Shortage Compound – Testosterone – effective February 23, 2023
- Drug Shortage Compound – Antibiotic Suspensions – effective Dec. 1, 2022 (Updated April 14, 2023)
- Drug Shortage Compound – Pediatric Acetaminophen (updated Dec. 1, 2022)
- Drug Shortage Compound – COTRIMOXAZOLE 40mg – 8mg per ml Oral Suspension
Claims Submission Procedure – Dispensing Frequency
- Frequency of Dispensing List (UPDATED May 2019)
- Form – Frequent Dispensing Authorization
Claims Submission Procedure – Claims with Cost Exceeding $9999.99
Claims Submission Procedure – Methadone (UPDATED August 2021)
- FAQ – Methadone (UPDATED August 2021)
Claims Submission Procedure – Pharmaceutical Distribution Rate Changes (UPDATED May 2019)
Claims Submission Procedure – Mifegymiso
List of Designated High-Cost Drugs for Reduced Pharmaceutical Distribution (UPDATED October 2023)
FAQ – Pharmacare Audit and Investigations
- Pharmacy Agreement Schedule “B” – Notice of Professional Fee Change
Form – Reversal/Adjustment
Template – Pharmacy Agreement

If your questions are not answered by reviewing the Claims Submission Procedures and FAQs provided here, please contact PDPInfoAudit@gov.mb.ca.

^ top

Manitoba Drug Benefits Formulary and Manitoba Drug Interchangeability Formulary

About the Manitoba Drug Benefits and Interchangeability Formularies

Bulletin Archive
This is the archive of Manitoba Drug Benefits and Interchangeability Formulary Amendments.
Manitoba Drug Benefits Formulary
A list of drugs and other items specified as eligible benefits under the Manitoba Pharmacare drug benefit program.
Manitoba Drug Interchangeability Formulary
A list of interchangeable drugs, categories and prices specific to drugs listed on the Manitoba Drug Benefits Formulary. Please note that Manitoba Pharmacare will reimburse only up to the lowest price in an interchangeable category for those interchangeable drugs which are Pharmacare benefits.
Effective date of transition from Regulation to Policy: October 18, 2021.

2022 Pan-Canadian Price Initiative

Manitoba Drug Formulary Lookup
Search the Manitoba Drug Benefits Formulary by brand name, active ingredient, Drug Identification Number (DIN); or more advanced search options such as Therapeutic Classification.
Manitoba Drug Formulary Glossary of Terms
EDS
Certain drugs are approved for coverage under the Exception Drug Status (EDS) Program when the use meets specific criteria as recommended by the Manitoba Drug Standards and Therapeutics Committee (MDSTC).
Effective October 18, 2021, "Part 3 Exception Drug Status" or "Part 3 benefits" will be referred to as "Exception Drug Status" or "EDS benefits".
pCPA
The pan-Canadian Pharmaceutical Alliance (pCPA) conducts joint provincial/territorial negotiations for brand name drugs in Canada to achieve greater value for publicly funded drug programs and patients.
CADTH Common Drug Review (CDR) Reports
Through the Common Drug Review (CDR) Process, CADTH conducts thorough and objective evaluations of the clinical, economic and patient evidence on drugs, and uses this evaluation to provide reimbursement recommendations and advice to Canada’s federal, provincial and territorial public drug plans.

^ top

Submitting New or Updated Pharmacy Information

DPIN Registration Form (Revised Feb. 28, 2023)

^ top

Current Topics & Client Resources

Pharmacare

Naloxone Kits

Take-Home Naloxone Program

Drug Shortages Canada

The website for reporting drug shortages and discontinuations in Canada.

^ top

Provincial Acts and Regulations

Provincial Acts and Regulations are available through the website of the Statutory Publications Office.

The Prescription Drugs Cost Assistance Act
- Prescription Drugs Payment of Benefits Regulation
- Specified Drugs Regulation
  This is the regulation that provides for the benefit lists of specified drugs under The Prescription Drugs Cost Assistance Act. It lists the drugs and criteria for eligibility for the Manitoba Pharmacare program.
  Effective: April 20, 2017
The Pharmaceutical Act
- Manitoba Drug Interchangeability Formulary
  This regulation under The Pharmaceutical Act includes a list of interchangeable drugs, categories and prices. Please note that Manitoba Pharmacare will reimburse only up to the lowest price in an interchangeable category for those interchangeable drugs which are Pharmacare benefits.
  Effective: April 20, 2017
The Personal Health Information Act (PHIA)
- PHIA - Information for Trustees
- The Personal Health Information Regulation
  This regulation has no legislative sanction and the original should be consulted for purposes of interpreting and applying the law.

^ top

Contact Information

Provincial Drug Programs
Manitoba Health
300 Carlton Street
Winnipeg MB R3B 3M9

PDP Information and Audit
PDPInfoAudit@gov.mb.ca
Fax: 204-786-8560

^ top